5943bf89-bad2-4461-8d80-7f9481810257
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- HEDGEHOG_SIGNALING+0.450
- MYOGENESIS+0.310
- UV_RESPONSE_DN+0.300
- ALLOGRAFT_REJECTION+0.290
- MITOTIC_SPINDLE+0.270
- INFLAMMATORY_RESPONSE+0.260
- APICAL_SURFACE+0.250
- ANGIOGENESIS+0.230
- IL6_JAK_STAT3_SIGNALING+0.230
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.600
- MYC_TARGETS_V1-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.450
- FATTY_ACID_METABOLISM-0.410
- MYC_TARGETS_V2-0.410
- DNA_REPAIR-0.360
- MTORC1_SIGNALING-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- ADIPOGENESIS-0.270
- GLYCOLYSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 17d3d480-5503-419e-92cd-cbc7db9659d2 | — | — | 0.899 |
| 2 | 3d8cce44-2cc8-464c-930c-78eb705bc4c8 | — | — | 0.864 |
| 3 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.861 |
| 4 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.860 |
| 5 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.849 |
| 6 | BSR_12_0175_A5_S64 | — | D | 0.835 |
| 7 | SRR6013528 | — | cohortSQ1 | 0.834 |
| 8 | SRR33346956 | — | — | 0.831 |
| 9 | SRR6013529 | — | cohortMD2 | 0.827 |
| 10 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.450 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.090 | Idelalisib | — uncovered |
| COMPLEMENT | 0.050 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |